日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control.

利用 LC-HRMS/MS 联合检测激活素受体信号通路抑制剂 (IASP) 用于人体兴奋剂检测

Sakellariou Panagiotis, Walpurgis Katja, Thomas Andreas, Marchand Alexandre, Miller Geoff, Dellanna Frank, Thevis Mario

Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan

透析依赖型慢性肾病患者血栓栓塞事件的危险因素:日本罗沙司他3期临床试验的汇总分析

Hamano, Takayuki; Yamaguchi, Yusuke; Goto, Kashia; Mizokawa, Sho; Ito, Yuichiro; Dellanna, Frank; Barratt, Jonathan; Akizawa, Tadao

Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials

透析依赖型慢性肾病患者血栓栓塞事件的危险因素:四项全球罗沙司他3期试验的汇总分析

Hamano, Takayuki; Yamaguchi, Yusuke; Goto, Kashia; Martin, Shaka; Jiletcovici, Alina; Dellanna, Frank; Akizawa, Tadao; Barratt, Jonathan

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

罗沙司他与促红细胞生成剂治疗非透析依赖性或新发透析慢性肾脏病贫血患者的安全性:四项3期研究的汇总分析

Barratt, Jonathan; Dellanna, Frank; Portoles, Jose; Choukroun, Gabriel; De Nicola, Luca; Young, James; Dimković, Nada; Reusch, Michael

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

一项随机、多中心3期研究比较了乙型肝炎疫苗HepB-CpG(HEPLISAV-B®)加强剂与HepB-Eng(Engerix-B®)和HepB-AS04(Fendrix®)在既往接种过乙型肝炎疫苗但未产生血清保护的接受血液透析的成年患者中的免疫原性和安全性:

Girndt, Matthias; Plüer, Manfred; Dellanna, Frank; Michelsen, Ann K; Beige, Joachim; Toussaint, Kai; Wehweck, Hubert J; Koch, Michael; Hafezi Rachti, Syrus; Faust, Justus; Bosselmann, Hans-Peter; Witzke, Oliver; Janssen, Robert S

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

索他西普的安全性和对血红蛋白、骨骼和血管钙化的影响

Coyne, Daniel W; Singh, Hem N; Smith, William T; Giuseppi, Ana Carolina; Connarn, Jamie N; Sherman, Matthew L; Dellanna, Frank; Malluche, Hartmut H; Hruska, Keith A

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis

PRS-080#22(一种铁调素拮抗剂)在健康志愿者和接受血液透析的慢性肾病患者中开展的首次人体I期研究

Renders, Lutz; Budde, Klemens; Rosenberger, Christian; van Swelm, Rachel; Swinkels, Dorine; Dellanna, Frank; Feuerer, Werner; Wen, Ming; Erley, Christiane; Bader, Birgit; Sommerer, Claudia; Schaier, Matthias; Meurer, Karoline; Matis, Louis

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

通过纠正血液透析中DOPPS确定的可改变做法,在5年内潜在获益的生命年数:来自欧洲MONITOR-CKD5研究的结果

Combe, Christian; Mann, Johannes; Goldsmith, David; Dellanna, Frank; Zaoui, Philippe; London, Gérard; Denhaerynck, Kris; Krendyukov, Andriy; Abraham, Ivo; MacDonald, Karen

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

HX575:已证实其在治疗肾性贫血方面具有生物相似性,并拥有10年的临床经验。

Dellanna, Frank; Goldsmith, David; Krendyukov, Andriy; Seidl, Andreas; Höbel, Nadja; Combe, Christian

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

促红细胞生成素生物类似药在肾性贫血治疗中的应用:我们从欧洲十年的经验中学到了什么?

Goldsmith, David; Dellanna, Frank; Schiestl, Martin; Krendyukov, Andriy; Combe, Christian